Ventripoint Diagnostics Reports Progress of the Next-Generation
VMS+ 3.0 System and Remote Workstation
Toronto, February 5, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce the development stage of their next-generation VMS+ 3.0 product is nearing completion. Usability studies are being initiated at two leading Canadian hospitals to establish effectiveness, efficiency, and ease of use of the VMS+ 3.0. The Company will be submitting for regulatory market approvals in North America and Europe as soon as these studies are completed.
The VMS+ 3.0 system is designed to use Artificial Intelligence (AI) to provide volumetric measurements and ejection fractions for all 4 chambers of the heart from standard 2D echo images. The system uses the new patent-pending position sensor system, which allows the patient to move during the imaging portion of the exam. The new ergonomic design makes for a compact and portable system that can be set-up within minutes. A new interactive guided workflow has been implemented on the VMS+ system to highlight view capture and point placement on each view to increase efficiency while performing imaging and analysis. Part of the strategy is to guide each clinician through the imaging procedure to help ensure more reliable and accurate results.
“Replacing the old magnetic tracking system with our new tracking sensor technology enables patient repositioning during the examination. This feature eliminates the usual restrictions on the person being scanned and will be instrumental in the ease of use by clinicians for both children and adults,” noted Dr. George Adams, CEO of Ventripoint.
The Company is also developing a workstation version of the VMS+ 3.0 software, which permits analysis of echocardiograms in a reading room elsewhere in the heart center or hospital. This will allow sonographers to continue to scan new patients, while studies are analyzed by cardiologists.
Ventripoint recently exhibited at a major European trade show providing live demonstrations of the VMS+ 3.0 system to 90 cardiac healthcare professionals. The system was well received with interest expressed by multiple heart centers to conduct clinical evaluations.
A new purchase order has been issued for the VMS+ heart analysis system by a Canadian cardiac institution (more details to follow).
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information or statements. In particular, this news release contains forward-looking information relating to the Offering and the use of the proceeds therefrom. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation, including expectations and assumptions concerning the completion of the Offering and the use of net proceeds of the Offering. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward looking statements and information because the Corporation can give no assurance that they will prove to be correct.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Such factors may include the failure to successfully market the Units and failure to satisfy certain conditions in connection with the issuance of the Units. Other factors which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.